Cancers, Vol. 15, Pages 5846: Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study

Cancers, Vol. 15, Pages 5846: Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study Cancers doi: 10.3390/cancers15245846 Authors: Ioannis Petrakis Christos Kontogiorgis Evangelia Nena Sosana Delimpasi Natasa E. Loutsidi Emmanouil Spanoudakis Stergios Intzes Christina Misidou Marianthi Symeonidou Nikolaos Giannakoulas Theodoros C. Constantinidis Evangelos Terpos Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma before analyzing findings in the context of respective real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, reasons for discontinuation, and the treatment duration per therapeutic algorithm. Data from 107 patients were collected. The median follow-up was 2.0 years. Of the subjects who met the selection criteria for the second LOT, 72.2% maintained the PFS at 52 weeks. In the third-line setting, the PFS rate at 52 weeks was 63....
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research